Congenital stem cell dysfunction associated with Turner-like phenotype.

K W Feldman; H D Ochs; T H Price; R J Wedgwood

doi:10.1016/s0022-3476(76)81055-4

Home/Archive/PubMed

PubMed · 1271198

Congenital stem cell dysfunction associated with Turner-like phenotype.

K W Feldman·H D Ochs·T H Price·R J Wedgwood

View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Bone Marrow Diseases Child, Preschool Female Hematopoietic Stem Cells Humans Phenotype Turner Syndrome Case Reports Journal Article Research Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

K W Feldman, H D Ochs, T H Price, R J Wedgwood. 1976. Congenital stem cell dysfunction associated with Turner-like phenotype.. https://doi.org/10.1016/s0022-3476(76)81055-4

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

MRI findings in Shwachman diamond syndrome.

Shwachman Diamond Syndrome (SDS) is a rare congenital disorder characterized by pancreatic insufficiency, bone marrow dysfunction, and skeletal changes. Because of the heterogeneous clinical presentation and the limits of laboratory tests that assess pancreatic insufficiency, the diagnosis of SDS can be challenging. Pancreatic lipomatosis, a typical feature of this syndrome, is also difficult to assess by direct tissue sampling. In these circumstances, magnetic resonance imaging (MRI) provides a readily available, noninvasive tool to evaluate the pancreatic fat content. We report a case of a 12-month-old male in which abdominal MRI was used to confirm the clinical diagnosis of SDS.

Bone Marrow Diseases↗

PubMed2007

Prenatal manifestation of pancytopenia in Pearson marrow-pancreas syndrome caused by a mitochondrial DNA deletion.

Explore the source record for details and available documents.

Bone Marrow Diseases↗

PubMed2006

Nuclear medicine imaging and therapy of neuroendocrine tumours.

Radiolabelled peptides are used for specific targeting of receptors (over-)expressed by tumour cells. Dependent on the kind of labelling and the radionuclide used, these compounds may be utilised for imaging or for therapy. A concise overview is provided on basic principles of designing and developing radiopeptides for these applications. Furthermore, clinical application of these compounds for imaging and therapy is described. Advantages of the method compared to other techniques (such as the use of radiolabelled antibodies or antibody fragments) are discussed as well as pitfalls and limitations.

Bone Marrow Diseases↗